Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
BTIG Maintains Bullish View on Paratek Pharmaceuticals (PRTK) Following Ad Com Briefing Docs
August 6, 2018 2:05 PM EDTBTIG analyst Robert Hazlett reiterated a Buy rating and $56 price target on Paratek Pharmaceuticals (NASDAQ: PRTK) following FDA briefing documents for Omadacycline.
Hazlett commented, "In our view, there appears little concern regarding ABSSSI (skin) indication for Wednesdays upcoming FDA Ad Com for Omadacycline; we view a recommendation for Omadacyclines approval in ABSSSI as highly likely. The... More
